Skip to main content
. 2024 Mar 8;13(6):e032256. doi: 10.1161/JAHA.123.032256

Figure 1. Overview of the metabolome‐wide screen for metabolites that modify risk of pulmonary arterial hypertension (PAH).

Figure 1

We performed a 2‐sample Mendelian randomization (MR) screen of 575 metabolites to identify those causally linked to PAH in a FinnGenn cohort. Metabolites that the passed Benjamini–Hochberg false discovery rate multiple testing correction were further evaluated by robust MR measures, sensitivity analysis, and in a validation FinnGenn PAH genome‐wide association study (GWAS). Finally, we directly measured these metabolites in an independent UK PAH cohort of 449 patients and demonstrated a correlation with disease severity.